A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

• Status: Terminated
• Trial end date: 2020-02-27
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Participants must have diagnosis of AD >= 12 months according to the American Academy of Dermatology criteria.

• Participants must have moderate to severe AD at screening and randomization.

• Participants must have inadequate response to topical medications within 6 months of screening (or history of intolerance).

Exclusion Criteria:

• Participants must not have concurrent treatment with topical or systemic treatments for AD.